123 related articles for article (PubMed ID: 9349930)
1. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.
Hildebrand M
Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of iloprost in patients with hepatic dysfunction.
Hildebrand M; Krause W; Angeli P; Koziol T; Gatta A; Merkel C; Bolognesi M
Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):430-4. PubMed ID: 1701761
[TBL] [Abstract][Full Text] [Related]
3. Characterization of oral sustained release preparations of iloprost in a pig model by plasma level monitoring.
Hildebrand H; McDonald FM; Windt-Hanke F
Prostaglandins; 1991 May; 41(5):473-86. PubMed ID: 1713701
[TBL] [Abstract][Full Text] [Related]
4. Oral iloprost in healthy volunteers.
Hildebrand M; Pfeffer M; Mahler M; Staks T; Windt-Hanke F; Schütt A
Eicosanoids; 1991; 4(3):149-54. PubMed ID: 1722988
[TBL] [Abstract][Full Text] [Related]
5. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group.
Eur J Vasc Endovasc Surg; 1998 Apr; 15(4):300-7. PubMed ID: 9610341
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease.
Hildebrand M; Krause W; Oberender HA; Zurdel-Dillinger S; Jünger M; Bodenburg H
Eicosanoids; 1990; 3(3):145-8. PubMed ID: 1700723
[TBL] [Abstract][Full Text] [Related]
7. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis.
Hildebrand M; Krause W; Fabian H; Koziol T; Neumayer HH
Int J Clin Pharmacol Res; 1990; 10(5):285-92. PubMed ID: 1706685
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of iloprost and cicaprost in mice.
Hildebrand M
Prostaglandins; 1992 Nov; 44(5):431-42. PubMed ID: 1281921
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.
Krause W; Krais T
Eur J Clin Pharmacol; 1986; 30(1):61-8. PubMed ID: 2423342
[TBL] [Abstract][Full Text] [Related]
11. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.
Grant SM; Goa KL
Drugs; 1992 Jun; 43(6):889-924. PubMed ID: 1379160
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
13. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Transcutaneous Monitoring in Long-Term Follow-Up of Patients With Thromboangiitis Obliterans Treated With Intravenous Iloprost.
Melillo E; Grigoratos C; Sanctis FD; Spontoni P; Nuti M; Dell'Omodarme M; Ferrari M; Balbarini A
Angiology; 2015 Jul; 66(6):531-8. PubMed ID: 25005765
[TBL] [Abstract][Full Text] [Related]
15. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
[TBL] [Abstract][Full Text] [Related]
17. Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Galyfos G; Kerasidis S; Kastrisios G; Giannakakis S; Sachmpazidis I; Anastasiadou C; Geropapas G; Papapetrou A; Papacharalampous G; Maltezos C
Vasa; 2017 Oct; 46(6):471-475. PubMed ID: 28753096
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Janssena MC; Wollersheim H; Kraus C; Hildebrand M; Watson HR; Thien T
Prostaglandins Other Lipid Mediat; 2000 Mar; 60(4-6):153-60. PubMed ID: 10751645
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs.
Schermuly RT; Schulz A; Ghofrani HA; Meidow A; Rose F; Roehl A; Weissmann N; Hildebrand M; Kurz J; Grimminger F; Walmrath D; Seeger W
J Pharmacol Exp Ther; 2002 Nov; 303(2):741-5. PubMed ID: 12388660
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms.
Hildebrand M; Staks T; Nieuweboer B
Eur J Clin Pharmacol; 1990; 39(2):149-53. PubMed ID: 2253664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
